Send to

Choose Destination
ACS Med Chem Lett. 2016 Sep 17;7(12):1077-1081. eCollection 2016 Dec 8.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Author information

Bristol-Myers Squibb R&D , 350 Carter Road, Hopewell Township, New Jersey 08540, United States.
Bristol-Myers Squibb R&D , 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States.


Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.


TF-FVIIa inhibitor; anticoagulant; fragment-based drug design; neutral P1

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center